证券代码：833230 证券简称：欧康医药 公告编号：2024-031 成都欧康医药股份有限公司 独立董事候选人声明与承诺 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人赵宇霆，已充分了解并同意由提名人成都欧康医药股份有限公司董事会 提名为成都欧康医药股份有限公司第四届董事会独立董事候选人。本人公开声明， 本人具备独立董事任职资格，保证不存在任何影响本人担任成都欧康医药股份有 限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人已同时符合以下条件： （一）具备上市公司运作的基本知识，熟悉相关法律法规、部门规章、规范 性文件及北交所业务规则； （二）具有五年以上履行独立董事职责所必需的法律、会计或者经济等工作 经验； （三）具有良好的个人品德，不存在重大失信等不良记录； （四）北交所规定的其他条件。 二、本人任职资格符合下列法律法规、部门规章和规范性文件及北交所业务 规则的要求： （一）《公司法》关于董事任职资格的规定； （十）其他法律法规、部门规章、规范性文件及北交所业务规则规定的情形。 三 ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-017 成都欧康医药股份有限公司 2024 年度租赁办公场所暨关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 为了公司日常经营发展业务需要，2024 年度，公司计划继续租赁办公场所 用于营销中心业务办公，此议案涉及关联交易，具体情况如下： 公司营销中心设在成都市光华中心办公，需要租赁办公场所，拟租赁赵卓君、 贾秀蓉、伍丽、刘印刚名下位于青羊区光华北三路 98 号 17 栋 1906 号房屋作为 公司营销中心的办公场所，预计年租金 153,161.52 元（含税）。 （二）决策与审议程序 2024 年 4 月 3 日，公司召开第三届董事会第一次独立董事专门会议，审议 通过《关于 2024 年度租赁办公场所暨关联交易的议案》，表决结果：同意票数 3 票，反对票数 0 票，弃权票数 0 票。 2024 年 4 月 15 日，公司召开第三届董事会第二十三次会议，审议通过《关 于 2024 年度租 ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-033 成都欧康医药股份有限公司 第三届董事会第二十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 15 日 2.会议召开地点：公司三楼会议室 3.会议召开方式：现场结合通讯方式 4.发出董事会会议通知的时间和方式：2024 年 4 月 4 日以书面方式发出 5.会议主持人：董事长赵卓君 6.会议列席人员：全体监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 独立董事潘鹰因工作原因以通讯方式出席会议。 二、议案审议情况 （一）审议通过《关于 2023 年年度报告及其摘要的议案》 1.议案内容： 根据《公司法》、《证券法》、《北京证券交 ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-011 成都欧康医药股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《中华人民共和国公司法》、《公司章程》及《利润分配管理制度》等相 关规定，成都欧康医药股份有限公司（以下简称"公司"）为积极履行回报股东 义务，与全体股东分享公司经营收益，在统筹考虑战略发展目标及流动资金需求， 保证公司健康、稳定、持续发展的前提下，公司拟实施 2023 年年度权益分派。 一、权益分派预案情况 三、公司章程关于利润分配的条款说明 根据《公司章程》规定，公司利润分配政策包括： 根据公司 2024 年 4 月 17 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 94,643,346.54 元，母公司未分配利润为 95,808,699.06 元。 公司本次权益分派预案如下：公司目前总股本为 75,631,404 股，以未分 ...

Financial Performance - Operating profit for the reporting period was CNY 16.79 million, a year-on-year decrease of 54.93%, primarily due to a significant drop in the price of quercetin products leading to reduced revenue[1]. - Net profit for the reporting period was CNY 16.48 million, down 51.04% year-on-year, attributed to declines in main business revenue and product gross margin[1]. - Main business revenue decreased by 11.13% year-on-year to CNY 237.54 million, while other business revenue increased by 147.39% to CNY 5.27 million[4]. - The gross profit margin for 2023 was 16.25%, down from 22.51% in 2022[71]. - The company's operating revenue for 2023 was approximately ¥242.81 million, a decrease of 9.88% compared to ¥269.44 million in 2022[71]. - The net profit attributable to shareholders for 2023 was approximately ¥16.67 million, representing a decline of 50.48% from ¥33.66 million in the previous year[71]. - The company's cash flow from operating activities for 2023 was approximately ¥36.13 million, a decrease of 35.36% from ¥55.90 million in 2022[72]. - The company's total assets at the end of 2023 amounted to approximately ¥453.09 million, reflecting a 2.87% increase from ¥440.47 million at the end of 2022[72]. - The total liabilities increased by 18.90% to approximately ¥59.72 million in 2023, compared to ¥50.23 million in 2022[72]. - The company's basic earnings per share dropped to CNY 0.22 for 2023, a decline of 61.40% from ¥0.57 in 2022[71]. Revenue and Sales - The company’s domestic sales revenue was CNY 191.15 million, a decrease of 13.43% year-on-year, while foreign sales revenue decreased by 0.24% to CNY 46.39 million[6]. - Sales of the company's flavonoid product from the Sophora japonica series decreased by 27.10% in volume and 41.93% in price, leading to a revenue drop of 57.67% for this product[90]. - Revenue for the fourth quarter reached CNY 73,028,535.30, marking a significant increase compared to previous quarters[78]. - The company reported a 21.58% year-on-year increase in sales revenue for Q4 2023, indicating a gradual recovery in business operations[90]. Research and Development - R&D expenditure for the current period is ¥13,509,643.28, representing 5.56% of operating revenue, an increase from 4.83% in the previous period[21]. - The company has a total of 33 R&D personnel, accounting for 15.87% of the total workforce, up from 13.88% last year[23]. - The company holds 37 patents, including 6 invention patents, an increase from 27 and 4 respectively in the previous period[23]. - The company has multiple ongoing R&D projects aimed at developing new products and production processes, which are expected to open new markets[28]. - The company is focusing on enhancing its R&D capabilities and product competitiveness to mitigate risks associated with market demand fluctuations and asset impairment[136]. Investments and Cash Flow - Cash flow from operating activities decreased by 35.36% year-on-year to CNY 36.13 million, mainly due to a reduction in cash received from sales of goods and services[10]. - Investment activities generated a net cash outflow of CNY 156.29 million, an increase of 129.73% year-on-year, due to ongoing construction of funded projects[10]. - The company has invested a total of ¥291,231,157.50 in financial products, with an outstanding balance of ¥93,612,040.12[14]. - The company has established OKAYPHARM USA INC. with a registered capital of USD 1 million, holding an 80% stake, and reported a net asset value of RMB 827,089.65 and a net loss of RMB -953,000.88 as of December 2023[176]. Market Expansion and Strategy - The company has established a new overseas subsidiary, OKAYPHARM USA INC., to enhance its international business capabilities, although it has not yet generated sales[18]. - The company is actively expanding its market presence in North America, Europe, and Japan, enhancing its global footprint[82]. - The company aims to stabilize its core business and increase market share by securing significant orders for key products and expanding its customer base[128]. - The company plans to enhance R&D and market investment to improve overall operational efficiency and achieve stable growth in performance in 2024[128]. Quality and Compliance - The company has established a comprehensive quality management system for pharmaceuticals, achieving multiple certifications including FSSC22000, HACCP, and ISO9001[82]. - The company has passed the GMP compliance inspection for its product Diosmin in July 2023, enabling further expansion into the domestic raw material market[48]. - The company has established strict product quality certification standards for its sales markets[129]. Risks and Challenges - The company has identified revenue recognition as a key audit matter due to the inherent risk of management potentially manipulating revenue recognition to meet specific targets[34]. - The company is aware of the potential impact of stricter environmental regulations and is prepared to incur higher costs to meet new standards[135]. - The company is facing risks related to the quality control of raw materials, which could affect its market position and operational performance[135]. - The company has no significant changes in major risks compared to the previous period, and there is no risk of delisting[59][60]. Corporate Governance - Zhao Zhuojun remains the controlling shareholder with a total ownership of 31,178,881 shares, accounting for 41.22% of the company[195]. - The total number of unrestricted shares increased from 15,705,531 to 18,907,851, representing a rise from 20.77% to 25.00% of total shares[194]. - The top ten shareholders collectively hold 76.31% of the shares, with a total of 57,722,890 shares[196].

证券代码：833230 证券简称：欧康医药 公告编号：2024-004 成都欧康医药股份有限公司 2023 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2023 年 年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2023 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2023 年年度主要财务数据和指标 二、经营业绩和财务状况情况说明 （二）业绩变动的主要原因 报告期内，公司净利润较上年同期下降 45.82%；扣非后净利润较上年同期 下降 54.89%。净利润下降的主要原因如下： （1）2023 年度，受到宏观经济环境变化、国际地缘冲突等因素的影响，市 场需求疲软，尤其是美国市场，客户以去库存、降产能为主，减缓采购，公司槐 米系列产品中槲皮素的销量受到较大影响，同比下降 27.10%，其销售价格同比 下滑 41.93%，导致槲皮素销售收入下降 57.67%。 （2）报告期内，植物提取行业竞争加剧，为稳固市场份额，公司对部 ...

Financial Performance - The estimated net profit attributable to shareholders for 2023 is expected to be 18.24 million yuan, a decrease of 45.82% compared to the same period last year, which was 33.66 million yuan [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be 14.23 million yuan, a decrease of 54.89% compared to the same period last year [4]. - The decline in net profit is attributed to intensified competition in the plant extraction industry and price reductions to maintain market share [5]. Sales and Market Trends - Sales revenue from the quercetin product line decreased by 57.67% due to weak market demand and significant price drops [5]. - The company experienced a 21.56% year-on-year increase in sales revenue in Q4 2023, indicating a gradual recovery in business operations [5]. Strategic Plans - The company plans to leverage its domestic GMP certification and food production licenses to expand into the domestic raw materials and food markets in 2024 [5]. - The company aims to optimize its product structure and enhance service capabilities to improve core competitiveness and profitability [5]. Investment Caution - The company emphasizes the importance of cautious investment decisions as the financial data for 2023 is preliminary and unaudited [6].

证券代码：833230 证券简称：欧康医药 公告编号：2024-002 成都欧康医药股份有限公司 关于获得 2023 年四川省节水型企业的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、基本情况 成都欧康医药股份有限公司（以下简称"公司"）近日收悉四川省经济和信 息化厅与四川省水利厅下发的《关于发布 2023 年省级节水型企业名单的通知》 （川经信环资函[2024]83 号），公司经过相关程序审定，获得 2023 年四川省节 水型企业称号。 二、对公司的影响 公司获得"2023 年四川省节水型企业"称号是对公司在节约用水工作中取 得成绩的肯定，是政府给予公司的一种荣誉。公司首先在生产经营管理上厉行节 约，努力提高公司节水管理水平和用水效率，发挥全体员工在节约用水、保护生 态环境中的引领作用，促进工业绿色低碳循环发展；同时促进用水的科学性与合 理性，深挖节水潜力，以管理抓节水、以制度促节水，积极采用节水新技术、新 工艺、新设备，淘汰落后用水工艺、设备器具等，减少了水资源的浪费，可降低 生产成本； ...

| | 公告日期 2024-02-06 异常期间 无 | | | | | --- | --- | --- | --- | --- | | | 欧康医药(833230) 连续竞价 1669649 （股） | 成交数量 | 成交金额（万 元） | 1749.83 | | | 当日价格振幅达到30%的前5只股票 涉及事项 | | | | | 买/卖 | 营业部或交易单元名称 | | 买入金额（元） | 卖出金额（元） | | 买1 | 海通证券股份有限公司舟山海山路营业部 | | 495754.04 | 0 | | 买2 | 国盛证券有限责任公司常州武青路营业部 | | 424924 | 0 | | 买3 | 招商证券股份有限公司深圳福华三路证券营业部 | | 408953.29 | 21820 | | 买4 | 兴业证券股份有限公司上海陆家嘴证券营业部 | | 401918.7 | 0 | | 买5 | 国信证券股份有限公司深圳罗湖人民南路证券营业部 | | 349765.2 | 0 | | 卖1 | 财达证券股份有限公司邢台郭守敬北路营业部 | | 0 | 1010804.75 | | 卖2 | 申万宏源西部证 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-02- | | | | | 异常期间涨跌幅偏离值累计 | | 06 | 833454 | 同心传动 | 40358281.0 | 46105.5 | 达到63.58% | | 2024-02- | 837663 | 明阳科技 | 18864500.0 | 24413.58 | 异常期间涨跌幅偏离值累计 | | 06 | | | | | 达到51.32% | | 2024-02- | 873570 | 坤博精工 | 2748272 | 11043.36 | 当日收盘价涨幅达到30.00% | | 06 | | | | | | | 2024-02- | | 九菱科技 | | | 当日收盘价涨幅达到29.99% | | 06 | 873305 | | 3389123 | 5593.54 | | | 2024-02- | 833454 | 同心传动 | 22575674.0 | 29572.71 | 当日收盘价涨幅达到29.97% | | ...